|Mr. Frederic Ors||Pres, CEO & Director||646.83k||N/A||1974|
|Mr. Pierre Labbé C.A., C.P.A., CPA, CA, ICD||Chief Financial Officer||423.49k||N/A||1965|
|Dr. Gabriela Nicola Rosu M.D.||Chief Medical Officer||384k||N/A||N/A|
|Mr. Joseph Sullivan||Sr. VP of Bus. Devel.||437.54k||N/A||N/A|
|Mr. Marc Jasmin CPA, CMA||Sr. Director of Investor Relations & Communications||N/A||N/A||N/A|
IMV Inc., a clinical-stage immuno-oncology company, together with its subsidiaries, develops products based on its platform and products with a primary focus on T cell activating therapies for cancer. The company's DPX drug development platform provides a patented delivery formulation that enables controlled and prolonged exposure of antigens to the immune system. The company develops DPX-Survivac, T cell activating immunotherapy that is in Phase II clinical trials for ovarian cancer and diffuse large B-cell lymphoma. It also develops DPX-RSV, a B cell epitope peptide vaccine candidate, which has completed a Phase I clinical trial for respiratory syncytial virus; DPX-E7 an investigational immunotherapy that targets a viral protein in human papillomavirus (HPV) known as E7; and vaccine candidates for malaria and the Zika virus. The company has collaboration and license agreement with Merck & Co., Inc., Dana-Farber Cancer Institute, Incyte Corporation, and Leidos Inc, as well as with Zoetis. The company was formerly known as Immunovaccine Inc. and changed its name to IMV Inc. in May 2018. IMV Inc. was founded in 2000 and is headquartered in Dartmouth, Canada.
IMV Inc.’s ISS Governance QualityScore as of N/A is N/A. The pillar scores are Audit: N/A; Board: N/A; Shareholder Rights: N/A; Compensation: N/A.